Skip to main content
. Author manuscript; available in PMC: 2015 Apr 1.
Published in final edited form as: Hematol Oncol Clin North Am. 2014 Jan 18;28(2):387–401. doi: 10.1016/j.hoc.2013.11.004

Figure 4. Modulation of hepcidin expression through genetic or pharmacological targeting of Tmprss6.

Figure 4

Loss of all endogenous Tmprss6 protein (A) leads to elevated levels of Hjv, the Bmp co-receptor, on the cell membrane. Significant hepcidin expression causes suppressed iron levels and a hypochromic, microcytic anemia, even in a mouse lacking Hfe. (B) Targeting of Tmprss6 thorough pharmacological means. Targeting of Tmprss6 siRNA to the liver in lipid nanoparticle (LNP)–formulated siRNAs, or by antisense oligonucleotide technology, leads to diminished Tmprss6 mRNA expression through classic RISC-mediated (cytoplasmic) or RnaseH-mediated (nucleus) suppression, respectively. Suppression of Tmprss6 causes elevated levels of Hjv to remain on the cell membrane, triggering heightened hepcidin expression and ameliorating the Hfe−/− phenotype.